Agios Pharmaceuticals price target raised to $53 from $51 at Scotiabank
The Fly

Agios Pharmaceuticals price target raised to $53 from $51 at Scotiabank

Scotiabank raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $53 from $51 and keeps an Outperform rating on the shares. The company has a strong quarter marked by continued achievement of important clinical development milestones, the analyst tells investors. With a favorable cash position, the firm believes the company is well-equipped to support the advancement of mitapivat in sickle cell disease, thalassemia, and its earlier clinical pipeline.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App